Clinical utility of cardiac troponin measurement in COVID-19 infection by Gaze, D. & Gaze, D.
On the Clinical Utility of Cardiac Troponin measurement in 
COVID-19 Infection
Journal: Annals of Clinical Biochemistry
Manuscript ID ACB-20-083.R1
Manuscript Type: Mini Review
Date Submitted by the 
Author: 25-Mar-2020
Complete List of Authors: Gaze, David; University of Westminster, Life Sciences; St George's 
University NHS Foundation Trust ,  Clinical Blood Sciences
Keywords: Troponin < Analytes
Annals of Clinical Biochemistry
DOI: 10.1177/0004563220921888
Mini Review
On the Clinical Utility of Cardiac Troponin measurement in COVID-19 Infection
Dr. David C. Gaze 
Lecturer in Clinical Biochemistry 
University of Westminster





Conflict of interest: None
Funding: This research received no specific grant from any funding agency in the public, 
commercial, or not-for-profit sectors.
Ethical approval: Not applicable
Guarantor: DCG
Contributorship: DCG sole author
Abstract
The novel coronavirus SARS-CoV-2 causes the disease COVID-19, a severe acute 
respiratory syndrome. COVID-19 is now a global pandemic and public health emergency 
due to rapid human-to-human transmission. The impact is far-reaching, with enforced social 
distancing and isolation, detrimental effects on individual physical activity and mental 
wellbeing, education in the young and economic impact to business. Whilst most COVID-19 
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patients demonstrate mild-to-moderate symptoms, those with severe disease progression 
are at a higher risk of mortality. As more is learnt about this novel disease, it is becoming 
evident that comorbid cardiovascular disease is associated with a greater severity and 
increased mortality. Many patients positive for COVID-19 demonstrate increased 
concentrations of cardiac troponin, creating confusion in clinical interpretation. Whilst 
myocardial infarction is associated with acute infectious respiratory disease, the majority of 
COVID-19 patients demonstrate stable cTn rather than the dynamically changing values 
indicative of an acute coronary syndrome.  Although full understanding of the mechanism of 
cTn release in COVID-19 is currently lacking, this mini-review assesses the limited published 
literature with a view to offering insight to pathophysiological mechanisms and reported 
treatment regimens.  
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The 7th coronavirus known to infect humans is currently proliferating in humans at an 
alarming rate. The latest virus named SARS-CoV-2 (previously 2019-nCov) causes the 
disease COVID-19, a severe acute respiratory syndrome (SARS). Following the initial 
outbreak in Wuhan, China in late 2019, the World Health Organisation (WHO) now considers 
SARS-CoV-2 a pandemic human viral infection. 
At the time of writing (25/3/2020, 12:30) the live situation dashboard of the WHO 
(https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd) reports 
375,498 global cases and 16,362 deaths in 195 countries, areas or territories. There are 
6,654 confirmed cases and 335 deaths in the United Kingdom.
There has been speculation that the virus was a result of genetic manipulation; however 
SARS-CoV-2 more likely originated by natural selection in an animal source. The current 
SARS-CoV-2 virus demonstrates similar genetics to bat SARS-CoV like coronaviruses1. 
There is however, no evidence of direct bat-to-human transmission, suggesting an 
intermediate animal host is involved. This follows similar zoonotic infection routes of other 
coronaviruses entering into the human population.
There has been a rapid response from the in vitro diagnostic industry to develop assays for 
SARS-CoV-2. These have migrated into UK laboratories at a much faster rate (50,442 tests 
on 18/3/20) than in the US, due in part to stringent Food and Drug Administration regulations 
(figure 1).  Real-time reverse transcription polymerase chain reaction (RT-PCR) is used for 
SARS-CoV-2 RNA viral detection in upper and lower respiratory specimens, and serological 
analysis of anti-COVID-19 antibodies by automated immunoassays can be used for disease 
surveillance. The preferred testing is by molecular diagnosis of COVID-19 by real-time RT-
PCR, such as the RdRp gene assay, which amplifies a conserved region of the RNA-
dependent RNA polymerase gene that is specific to SARS-CoV-2, which has been used for 
confirmation of this disease by Public Health England laboratories. In addition, 
oligonucleotide primers and probes selected from regions of the virus nucleocapsid (N) gene 
are also included in the panel. In confirmed COVID-19 cases, the laboratory testing should 
be repeated to demonstrate viral clearance prior to healthcare discharge.  
Incubation, Transmission and Clinical Presentation
The incubation period has been suggested to be approximately 5 days2. Transmission is 
dependent on variable individual infectiousness, population density and spatial distance. The 
virus is transmitted primarily in respiratory aerosols and by indirect contact with 
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contaminated surfaces. Faecal analysis detecting viral RNA also suggest a faecal-oral route 
of transmission3.
The clinical presentation and severity of symptoms is case-dependent. The clinical 
characteristics in the Chinese population have been recently documented from 1,099 
cases4. The virus has infected more males than females and severity is associated with 
older age. The common symptoms are fever and a persistent non-productive cough, 
although many present without fever and often with mild symptoms. The vast majority 
(>85%) do not demonstrate chest radiographic abnormalities; but ground-glass opacity and 
bilateral shadowing has been demonstrated on computer tomography in severe cases. 
Laboratory Findings
Evidence from the Chinese cohort suggests prominent lymphocytopenia occurs in 83% of 
cases, with thrombocytopenia in 36% and leukopenia in 34%. Biochemically, patients 
demonstrate high concentrations of C-reactive protein (CRP) and less common elevations in 
liver enzymes (aspartate aminotransferase and alanine aminotransferase), creatine kinase 
(CK) and D-dimer4.  Furthermore, in a systematic analysis of eleven articles, Lippi and 
Plebani have documented laboratory abnormalities reported in cases of COVID-195. Patients 
may also present with decreased albumin, or increases in lactate dehydrogenase, total 
bilirubin, creatinine, procalcitonin and also cardiac troponin and natriuretic peptides. 
Cardiac Troponin elevations in COVID-19
Previous influenza infection epidemics have been associated with myocardial infarction, 
myocarditis and exacerbated heart failure6. These comorbid conditions contribute to 
significant mortality. Previous coronarvirus epidemics such as SARS in 2002 and Middle 
East Respiratory Syndrome (MERS) were associated with tachycardia, bradycardia, 
cardiomegaly, cardiac arrest, sub-clinical diastolic impairment and acute-onset heart failure7-
11. 
COVID-19 is characterised by pneumonia and persons with underlying cardiovascular 
disease associated with hypertension, diabetes, coronary artery disease or cerebral vascular 
disease are at higher risk of developing the severest from of the disease and demonstrate 
the highest rate of mortality (figure 2). Cardiac complications include the development of 
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incident heart failure, acute coronary syndrome (ACS) and arrhythmia all of which are 
associated with elevation in cTn12 especially when using high sensitivity immunoassays and 
confer poor prognosis. Elevations in cTn are common in those with acute infectious 
respiratory disease and increases correlate with the severity of infection13. 
Evidence of COVID-19-associated increases in circulating cardiac troponin T (cTnT) and 
cardiac troponin I (cTnI) above the 99th percentile reference limit are emerging in the 
literature14-17. Detectable cTnI has been observed in most COVID-19 patients. In a 
retrospective cohort analysis cTnI was significantly elevated in 54 subjects who died 
compared to 137 survivors (median [IQR] cTnI 22 [5.6–83.1] ng/L vs 3 [1.1-5.5] ng/L, 
p=<0.0001)18. 
The mechanism of cTn elevation in COVID-19 infection is not fully understood. Elevations 
are likely to reflect non-coronary disease rather than acute coronary disease such as 
myocardial infarction19. The underlying pathophysiology is suggestive of a cardio-
inflammatory response as many critically ill COVID-19 patients demonstrate concomitant 
elevations in acute phase reactants such as CRP and the natriuretic peptides. This may 
present clinically as fulminant myocarditis. 
In one case report,20 a thirty seven year old male presented with a three-day history of chest 
pain and dyspnoea. Electrocardiographic changes suggested an ST-segment elevation 
acute myocardial infarction and cTnT was substantially elevated at >10,000 ng/L (99th 
percentile reference limit <14 ng/L), with concomitant elevations in CK and b-type natriuretic 
peptide. The initial working diagnosis was ACS. Subsequent CT coronary angiography 
revealed no evidence of coronary stenosis. A sputum sample was assayed for 13 viral 
nucleic acids of which only coronavirus was positive. the working diagnosis changed to 
coronavirus fulminant myocarditis with cardiogenic shock and pulmonary infection. The 
patient was successfully treated with glucocorticoid and human Ig and cTnT decreased to 
220 ng/L by one week and 21 ng/L by three weeks.
A further mechanism for consideration involves angiotensin converting enzyme 2 (ACE2) 
which is expressed in myocardial tissue. SARS-CoV-2 binds cells expressing ACE221. 
Binding of the virus can down-regulate ACE2 intracellular pathways and mediate 
inflammation and oedema, contributing to respiratory failure22. In theory this could have a 
potential impact on patients taking ACE inhibitors (ACEi), resulting in greater risk of 
acquiring COVID-19 infection and increased severity of disease. However, at present the 
European Society of Cardiology has highlighted a lack of scientific evidence regarding 
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COVID-19 infection in patients on ACEi or angiotensin receptor blockers, and supports 
continuation of antihypertensive therapy in patients with confirmed infection (ESC.org). 
Concluding Summary
The epidemiology of COVID-19 infection is evolving rapidly. As new cases are identified, 
understanding of clinical and diagnostic presentations is being refined. Cardiac biomarkers, 
in particular cTn and natriuretic peptides, are commonly elevated in patients with COVID-19 
disease. As with many other non-ACS pathologies, elevation of cTn is associated with 
disease severity and poor prognosis. With the fast-moving development of disease 
progression across the globe and with better understanding of the mechanisms of 
cardiovascular complications in COVID-19, cardiac biomarkers can be utilised as a metric of 
a worsening clinical scenario or as an indicator of improving response due to 
cardioprotective intervention.   
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Figure 1: Global utilisation of COVID-19 testing. (Source: https://ourworldindata.org/covid-
testing). 
Figure 2: COVID-19 mortality rate in patients with pre-existing diseases. CRD, Chronic 
Respiratory Disease; CVD, Cardiovascular Disease. (Data source: Johns Hopkins University 
Centre for Systems Science and Engineering)
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